Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin Compared to Sequential Metformin Therapy in Newly Diagnosed Type 2 Diabetes Patients

NCT06417489 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT06417489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06417489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin Compared to Sequential Metformin Therapy in Newly Diagnosed Type 2 Diabetes Patients
Lead sponsor
Peking University First Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
May 31, 2024
Completion date
December 31, 2026
Enrollment
160 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes